Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - Aipeng Medical (300753) announced that its shareholder, Beijing Zhanghong Private Equity Fund Management Co., Ltd. - Zhanghong Selected No. 1 Private Securities Investment Fund, plans to reduce its stake by up to 2% of the company's shares [1] Summary by Category Shareholder Actions - Zhanghong Selected No. 1 plans to reduce its holdings by no more than 1.26 million shares, which represents 1% of the total share capital of the company, through centralized bidding within three months after a 15 trading day period following the announcement [1] - Additionally, the fund intends to reduce another 1.26 million shares, also representing 1% of the total share capital, through block trading within the same timeframe [1] Current Holdings - As of the announcement, Zhanghong Selected No. 1 holds 7.058 million shares, accounting for 5.6% of the company's total share capital [1]

Core Viewpoint - Aipeng Medical (300753.SZ) announced that its major shareholder, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its holdings in the company through both centralized bidding and block trading methods, affecting a total of up to 252,100 shares, which represents 1% of the company's total share capital [1] Group 1 - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, intends to reduce its holdings by up to 126,050 shares through centralized bidding within three months after a 15 trading day period from the announcement [1] - Additionally, the same shareholder plans to reduce its holdings by up to 126,050 shares through block trading within the same timeframe [1]

Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its holdings in Aipeng Medical (300753.SZ) by up to 1% of the total share capital through both centralized bidding and block trading within three months after the announcement [1] Group 1 - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, intends to sell no more than 1,260,500 shares, which represents 1% of the company's total share capital [1] - The planned reduction will occur in two phases: through centralized bidding and block trading, each not exceeding 1% of the total share capital [1]

Core Viewpoint - Aipeng Medical (300753) announced that its shareholder, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its stake by up to 2% through centralized bidding or block trading [1] Group 1 - The shareholder holds a 5.6% stake in Aipeng Medical [1] - The reduction in stake will be executed through either centralized bidding or block trading methods [1]

Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its stake in Aipeng Medical by up to 1,260,480 shares, representing 1% of the total share capital, due to personal funding needs [1] Group 1 - The shareholder holds 7,058,000 shares, accounting for 5.60% of the company's total share capital [1] - The planned reduction will occur within three months starting from fifteen trading days after the announcement date, specifically from December 4, 2025, to March 3, 2026 [1] - The reduction will be executed through centralized bidding and block trading methods, with the selling price determined by market conditions [1] Group 2 - The shares being reduced were acquired through an agreement transfer in 2024 [1] - The shareholder is not classified as a controlling shareholder or actual controller of the company, ensuring that the reduction will not lead to a change in control or affect the company's governance structure and ongoing operations [1]

Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its stake in Aipeng Medical by selling up to 252.1 thousand shares, which represents 2% of its holdings, due to its own funding needs [1] Group 1: Shareholding Details - Beijing Zhanghong Private Fund Management Co., Ltd. currently holds 7.058 million shares of Aipeng Medical, accounting for 5.60% of the total shares [1] - The shares to be sold consist of 126.05 thousand shares through centralized bidding and another 126.05 thousand shares through block trading, both representing 1% of the total shares [1] Group 2: Timeline and Pricing - The reduction period is set from December 4, 2025, to March 3, 2026 [1] - The selling price will be determined based on market prices during the reduction period [1]

江苏爱朋医疗科技股份有限公司 关于持股5%以上股东减持股份的预披露公告 公司持股5%以上的股东北京章泓私募基金管理有限公司-章泓精选1号私募 证券投资基金保证向公司提供的信息内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：持有本公司7,058,000股（占公司总股本的5.60%）的持股5%以上股东 北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金（以下简称"章泓精 选1号"）计划自本公告发布之日起十五个交易日后的三个月内以集中竞价交易方式减 持所持有的本公司股份不超过1,260,480股（占公司总股本的1%）；计划自本公告发布 之日起十五个交易日后的三个月内以大宗交易方式减持所持有的本公司股份不超过 1,260,480股（占公司总股本的1%）。 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-052 | | | 在减持计划实施期间，公司若发生派发红利、送红股、转增股本、增发新股或配 股等除权、除息事项，减持股份数量、股权比例将进行相应调整。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]